Penester( finasteride) analog:
Penester( finasteride) Instruction:
Operating substance of Penestrier:
Who is shown the Penester?
Finasteride is intended for the therapy and control of the progression of BPH.To reduce the risk of acute urinary retention, reducing the risk of surgical intervention, including. Transurethral resection of the prostate and prostatectomy.
How to use Penester?
The patient is usually given 1 tablet a day. To achieve a clinical effect in most cases, a course of treatment of 6 to 12 months is required. Dose changes are generally not necessary, even in cases of renal insufficiency( creatinine clearance up to 0.9 ml / min).In cases of liver failure, treatment should be performed under the supervision of a physician, since finasteride is metabolized in the liver.
Patients with a large volume of residual urine or with an expressive urinary retention should be monitored continuously to prevent their development of obstructive uropathy.
Isolation of finasteride with milk has not been established.
Small amounts of finasteride were found in semen. In this regard, pregnant women and women of childbearing age should not directly contact the sperm of patients who are treated with finasteride.
Finasteride does not affect the performance of patients, their cognitive and sensory abilities, decision making, the ability to drive vehicles, mechanical devices, perform work at altitude, etc.
Effect on the concentration of specific prostate antigen( PSA) in the serum and the development of prostate cancer: inControlled clinical trials on groups of patients with BPH and simultaneously, their PSA levels increased, the frequency of degeneration of BPH in a cancer tumor during the period of long-term care was not statisticallyLichalas in two alternative groups( one was treated with finasteride, the other was given a placebo).Before starting treatment with finasteride, and in the future, patients with BPH are advised to periodically perform a rectal finger examination of the prostate and other diagnostic studies to exclude possible cancer.
Effect on laboratory tests: serum PSA concentration depends on the patient's age and prostate size, and also increases with age. In patients who are treated with finasteride, the concentration of PSA is usually reduced. In most cases, during the first month of therapy there is a rapid decrease in PSA, but then its level is stabilized. After a 6-month course of treatment, the PSA concentrations are only half of the baseline levels and significantly lower( ≈ 50%) compared to other BPH patients who have PSA statistic.
Side effects of Penester.
The most common side effects in the treatment of finasteride were sexual disorders such as decreased sexual desire( libido), decreased sperm volume, impotence. There was also an increase in the size of mammary glands in men( gynecomastia), but this phenomenon disappeared after the interruption of therapy. Allergic reactions are possible( skin rash, itching, facial swelling, testicular pain).
Who is contraindicated in Penester?
Hypersensitivity in patients to the active ingredient or other constituent components of the drug. Finasteride is generally unintended for women. It can cause anomalies of the genital organs in the male embryo developing in the uterus. This teratogenic effect was established in animal experiments. It is obviously associated with the blockade of the metabolic transformation of testosterone into dihydrotestosterone.
Interaction of the Penester.
Any clinical expression of finasteride interaction with other drugs has not yet been established( including propranolol, digoxin, glibenclamide, warfarin, theophylline, antipyrine).Finasteride has no significant effect on the enzymatic system of drug metabolism associated with cytochrome P-450.
Overdose of Penester.
No clinical cases of overdose of finasteride have been reported so far. In case of an overdose, it is recommended to limit yourself to symptomatic therapy.